Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Rating) CFO Douglas Devine sold 10,109 shares of the business’s stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $114.22, for a total transaction of $1,154,649.98. Following the completion of the transaction, the chief financial officer now owns 29,702 shares of the company’s stock, valued at $3,392,562.44. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Douglas Devine also recently made the following trade(s):
- On Tuesday, July 5th, Douglas Devine sold 1,239 shares of iRhythm Technologies stock. The shares were sold at an average price of $108.90, for a total transaction of $134,927.10.
Shares of iRhythm Technologies stock traded down $6.99 during trading on Monday, reaching $134.73. 21,632 shares of the company traded hands, compared to its average volume of 403,202. The company has a quick ratio of 4.43, a current ratio of 4.63 and a debt-to-equity ratio of 0.14. iRhythm Technologies, Inc. has a 1-year low of $41.66 and a 1-year high of $169.54. The company has a 50 day moving average price of $126.32 and a 200-day moving average price of $129.38.
iRhythm Technologies (NASDAQ:IRTC – Get Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.26. iRhythm Technologies had a negative net margin of 36.43% and a negative return on equity of 34.55%. The company had revenue of $92.40 million for the quarter, compared to the consensus estimate of $86.76 million. During the same quarter in the previous year, the company earned ($0.95) EPS. iRhythm Technologies’s quarterly revenue was up 24.4% compared to the same quarter last year. As a group, sell-side analysts predict that iRhythm Technologies, Inc. will post -3.26 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRTC. Royal Bank of Canada raised its holdings in iRhythm Technologies by 5.9% during the third quarter. Royal Bank of Canada now owns 28,738 shares of the company’s stock worth $1,683,000 after buying an additional 1,602 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in iRhythm Technologies by 57.9% during the third quarter. Bank of New York Mellon Corp now owns 344,202 shares of the company’s stock worth $20,156,000 after buying an additional 126,196 shares during the last quarter. Parallel Advisors LLC raised its holdings in iRhythm Technologies by 380.9% during the fourth quarter. Parallel Advisors LLC now owns 630 shares of the company’s stock worth $74,000 after buying an additional 499 shares during the last quarter. Strs Ohio acquired a new position in iRhythm Technologies during the fourth quarter worth $1,294,000. Finally, Fieldpoint Private Securities LLC raised its holdings in iRhythm Technologies by 31.3% during the fourth quarter. Fieldpoint Private Securities LLC now owns 1,808 shares of the company’s stock worth $213,000 after buying an additional 431 shares during the last quarter. Hedge funds and other institutional investors own 97.92% of the company’s stock.
Several equities research analysts recently issued reports on IRTC shares. StockNews.com started coverage on shares of iRhythm Technologies in a report on Thursday, March 31st. They set a “sell” rating on the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $135.00 price target (down from $183.00) on shares of iRhythm Technologies in a report on Wednesday, June 22nd. Truist Financial reduced their target price on shares of iRhythm Technologies from $200.00 to $165.00 and set a “buy” rating on the stock in a report on Thursday, June 16th. Citigroup lowered shares of iRhythm Technologies from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, June 9th. Finally, Wolfe Research assumed coverage on shares of iRhythm Technologies in a report on Tuesday, April 5th. They set an “underperform” rating and a $105.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $153.67.
About iRhythm Technologies (Get Rating)
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Further Reading
- Get a free copy of the StockNews.com research report on iRhythm Technologies (IRTC)
- Five Below Stock is a Recession Play
- Here’s How to Dollar Cost Average into Positions in a Bear Market
- MarketBeat: Week in Review 7/4 – 7/8
- AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
- Levi Strauss Proves Resilient For Dividend Investors
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider iRhythm Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and iRhythm Technologies wasn’t on the list.
While iRhythm Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Today Kate chats with Peter Tanous, investment advisor and author of “The Pure Equity Plus Plan: Your Path To A Multi-Million Dollar Retirement.” Peter offers a perspective that’s quite different from the typical advisor’s view of broad international diversification.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.
